NCT06318897View on ClinicalTrials.gov

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Stage 1 cT1b-T1cN0M0Triple Negative Breast Cancer
Interventions
DRUG

Carboplatin

Given by IV

DRUG

Paclitaxel

Given by IV

DRUG

Pembrolizumab

Given by IV

DRUG

Doxorubicin

Given by IV

DRUG

Cyclophosphamide

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER